Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD Trial of Retatrutide in Patients With Chronic Kidney Disease

RET-STUDY-P032

Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2026;41(6):1058–1068. DOI: 10.1093/ndt/gfaf230. PMID: 41160422. PMCID: PMC13218929. NCT05936151. Design and baseline publication only. https://pmc.ncbi.nlm.nih.gov/articles/PMC13218929/

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reference ledger

P032Peer-reviewed human trials and related publications

Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD Trial of Retatrutide in Patients With Chronic Kidney Disease

Heerspink HJL; van Raalte DH; Bjornstad P; Bunck MC; Wu P; Tunali I; Milicevic Z; Koeneman L. Nephrology Dialysis Transplantation. 2026;41(6):1058–1068. PMID: 41160422. PMCID: PMC13218929. NCT05936151.(2026). DOI: 10.1093/ndt/gfaf230

Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD Trial of Retatrutide in Patients With Chronic Kidney Disease

Record details

Endpoints, findings, and limitations

Reference ledger

First Due Biotech